We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
30p could go very soon especially if Mo surprises us with more big contract news at results update in April.
March 28 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Carnival, Diploma and Rational AG on Thursday.
Following is a summary of research actions on European companies reported by Reuters on Thursday.
Hvivo Plc : Peel Hunt initiates coverage with buy rating; PT 36p
Advanced Medical Solutions Group Plc : Berenberg raises PT to 300p from 290p
AFC Energy Plc : Liberum cuts target price to 68p from 85p
Belimo Holding AG : Berenberg cuts PT to CHF 530 from CHF 570
Carnival : Macquarie raises target price to 1900p from 1700p
CMC Markets Plc : Jefferies raises target price to 135p from 127p
DFS Furniture Plc : Berenberg cuts target price to 120p from 180p
DFS Furniture Plc : Berenberg cuts to hold from buy
Diploma Plc : HSBC raises target price to 4275p from 3880p
Diploma Plc : Jefferies cuts to hold from buy
Diploma Plc : Jefferies raises target price to 3,950p from 3,750p
El En SpA : Berenberg raises target price to EUR 13.1 from EUR 11.5
El En SpA : Berenberg raises to buy from hold
Forterra Plc : Peel Hunt cuts to hold from add
Hochschild : RBC raises target price to 150p from 140p
Kion Group AG : Jefferies cuts target price to EUR 60 from EUR 61
Millicom : JP Morgan raises target price to SEK 260 from SEK 190
Millicom : JP Morgan raises to overweight from neutral
Nordea Bank Abp : Berenberg raises PT to SEK 153 from SEK 150
Rational AG : Berenberg raises target price to EUR 760 from EUR 640
Reckitt : Jefferies raises target price to 4,100p from 4,000p
Redeia Corporacion SA : JP Morgan raises PT to EUR 15.6 from EUR 14.4
Safran : Citigroup raises target price to EUR 211 from EUR 161
Siemens Energy AG : JP Morgan raises PT to EUR 11.4 from EUR 9.9
Softcat Plc : Liberum raises target price to 1670p from 1440p
Teleperformance SE : RBC cuts target price to EUR 125 from EUR 210
Terna : HSBC raises target price to EUR 9.1 from EUR 8.4
Ditto
Two great summarising posts!
HVO is a great "core of portfolio" company.
- The leadership has a steady and undramatic management style;
- Meeting and exceeding their guidance;
- Transitioning to a regular dividend-paying company;
- Offering a category of services that others are unable to, with a very high barrier to entry (moat);
- Offering a strong value proposition to customers that easily pays for itself via either faster time-to-market or early project termination. This is a game-changer versus years of preclinical and P1 trials to determine basic efficacy;
- Enables categories of therapeutic to come to market that have proven impossible to test before. For example, pathogens which are very seasonal and/or exhibit unpredictable wave-like patterns of transmission in their epidemiology (e.g. a burst of severe cases rapidly transmitting, but disappears for a few years until the next cycle). HVO can control that process, rather than you having to pray that the disease will be present in the community when you kick off your P1 study;
- Good margins, gash generative, plenty of reserves for either dividend payouts or bolt-on acquisitions. No debt;
- Customers with plenty of cash and a long pipeline of new business opportunities more pathogens become accepted candidates for human challenge trials;
- Increasingly good regulatory acceptance of human challenge trials data, as evidenced by comments/data Mo' shared from customers.
Those are just some of the reasons, off the top of my head. It's really a completely unique proposition.
We are on the cusp of a real coming of age with the move to Canary wharf. A very grown up company. I can't fathom why people would be selling right now as we keep knocking on the door of 30p and I presume soon enough we'll break and never see the 20s again!
Increasing revenues
Increasing margins
Increasing profit
Increasing market
Global leader
Clients paying us for our move
JPMorgan buying
Dividend coming
Results coming
New financial year (ISAs incoming)
Unquestionable business model
There's too much going for us and no discernable downside
My thoughts exactly, the company is a million miles ahead of where it was just 3 years ago when the price spiked at 47p. With well over £30 million in the bank and the new Client paid for facilities at Canary Wharf opening in a couple of months. Hvivo appears to be going places and let's not forget Hvivo is the World leader in its specialised field of HC trials and has a moat so wide Apple would probably be jealous of Hvivo's leading position. I just can't see anyone getting in on Hvivo's market anytime soon eith so many regulatory barriers in the way to new entrants. What Pharma company would want to switch away from their long term partner who has 30 plus years of expertise and knowledge. JMO Adyor! GLA
Hi All long term holders. I have been with this from the Open Orphan Covid highs down to the post Covid hVIVO lows.
I have significant exposure (like many probably too much exposure). I am relieved to be back up, knocking on the door of 30p again.
I thought I would be more inclined to sell as the share price recovered, but with the new facility coming online, a very healthy order book and long term visibility, JP Morgan taking a sizable stake, another dividend on its way and increased diversity in the challenge studies offered, I find myself happy to continue holding and see how this plays out.
The share price has been much less volatile with positive sentiment and increased institutional ownership giving it more of a platform. Also the business itself is solid with positive cash flow and money in the bank.
Some talk of a sale, but I think regardless of what happens, things are looking really good. If the upcoming results underpin all of this, which I think they will, my instinct is that we will move up to the low 30s in the medium term. If news unknown news, such as M&A, or contracts that show the size of the company's bigger contract abilities, a few more TR1s, or something like a malaria trial I think these could move the share price into new territory. GLA.
Quietly creeping back towards 30p...I wonder if we'll get another big contract signing soon 🤔? Would be great to see one of the new Challenge Models being signed, maybe a Covid trial in the new Canary Wharf facilities?
Lol, maybe they'll give you a free dose of Malaria to go with the chocolate digestives...
Shareholders get chocolate on their daily digestive biscuits!
I'm tempted to volunteer and book myself in for a week when they open, and see if I can get any shareholder perks!!
Not long now until the brand new expanded facilities open in Canary Wharf. Expecting big news seeing as big pharmaceutical clients have paid for the new facilities to get their drugs prioritised so it would seem. Looking like 2024 is going to be a big year for Hvivo under Mo's brilliant stewardship. GLA Adyor!
Don't stress yourself, not one single person was "taking your word for it"
I don’t think stt1 has heard the term ad nauseam.
Ricky,
"Stt is constantly talking Hvivo down saying questionable business model, no Institutional investors, low growth etc etc"
That's because I see a questionable business model.
Can you provide evidence where I've said NO IIs to prove you're not making things up or misquoting me?
I've deep concerns about their business model. It's a questionable business model.
I had concerns about other company's business models, CEO options etc. Those company shares went onto crash.
Readers, don't take my word for it. The evidence is in my 2 posts on TLY dated 21st March around 12pm and 1pm.
https://www.lse.co.uk/profiles/stt1/
The options were back dated a year. Look at the company newsflow since the CEO joined in 2022 and then compare that to the repeated media tips over the past 6 months.
There have been several media tips, presentations since around Christmas. The CEO's options are exercisable from around a year. I don't think that's a coincidence.
There's no evidence of significant buying/holding by institutionS. CEO's options are exercisable within a year. Over the past few months, some IIs have bought a few. 1 now holds > 5%.
The shares are being talked up and CEO's options due within a year. I don't see that as a coincidence.
The Chairman/Founder dumped majority of his holding last month. This was after the shares were talked up in media and presentations.
The Chairman dumping majority of his holding so soon after they were being talked up is a red flag imo.
From company rns
"The LTIP has been designed to reward, incentivise and retainMr Khan to deliver sustainable growth for shareholders. The deemed date of award is 24 February 2022, which is the date Mr Khan was appointed CEO. Under the LTIP,Mr Khan has been awarded 7,227,273 nominal cost long term incentive options ("LTIP Options " ) over ordinary shares of £0.001 each in the Company.
Vesting of the LTIP Options is conditional upon a three-year total shareholder return ("TSR") performance against an initial 11p reference price. A portion of the LTIP Options will vest on the third anniversary of the date of award subject to the achievement of a minimum 10% CAGR TSR performance increasing on a straight-line basis to vesting in full subject to the achievement of a 22.5% CAGR TSR performance. The award of the LTIP Options is also subject to continued employment, malus and clawback provisions and will vest in full on a takeover of the Company."
https://polaris.brighterir.com/public/hvivo/news/rns/story/x21q5mw/export
Ricky,
"STT Mo Khan’s LTIP is for the period ended Feb 25 "
That's what I've been saying. More posters are realising what I've been saying and repeating the same.
The CEO was awarded huge 7m options a year ago, exercisable from a year's time.
There's no evidence of significant buying/holding by IIs 2021, 2022, 2023 then over the past few months and just months before CEO's options are exercisable, some have bought tiny amounts. 1 has bought > 5%.
With several media tips, presentations etc, the shares are being talked up since the options are due to become exercisable from less than a year's time.
Seriously guys. Lighten up. My dig was a little joke. No one could take stt seriously
B - if you read this regularly you will note that Stt is constantly talking Hvivo down saying questionable business model, no Institutional investors, low growth etc etc and may actually put people off the Company. A little dig back is not going to hurt too much
Please tell me what benefit you get from this post?
I pop on her regularly & mostly its for good quality info.
Then I read this..! Honestly grow up & ignore him.
Stt. Can you give us all a list of the companies you hate. Seems contrarianism isn't working for you. I will put 5k in each of the companies you hate and expect to be rich soon. As Delboy said "this time next year I'll be a millionaire"
Indeed - hard to see any red flags unless you are colour blind hoho.
Yip, can only take this as a positive
You may have seen that hVIVO has issued a new TR1 this afternoon, which reflects the increase in JP Morgan’s shareholding to 7.03% in HVO
https://polaris.brighterir.com/public/hvivo/news/rns/story/rdlj28x
This follows on from their TR1 published on Thursday 14 March. I am sure HVO are delighted to see such a large fund heavily invested in the company!!